A Chinese drugmaker said it has started mass-producing an experimental drug from Gilead Sciences that has the potential to fight the novel coronavirus, as China accelerates its effort to find a treatment for the widening outbreak. Suzhou-based BrightGene Bio-Medical Technology said in a statement filed to the Shanghai Stock Exchange on Tuesday night that it has developed the technology to synthesize the active pharmaceutical ingredients of remdesivir, Gilead’s drug that is a leading candidate to treat the highly-infectious virus that’s killed more than 1,000 people.
A Chinese Drugmaker Has Started Mass-producing An Experimental Drug For Covid-19
Bloomberg, Time
Tue, 02/11/2020 - 10:35pm
Topics: gilead sciences suzhou-based brightgene bio-medical technology stock exchange while brightgene american large u.s chinese wuhan gilead brightgene&rsquo world health organization bloomberg chinese china brightgene shanghai gilead&rsquo u.s brightgene started mass-producing an experimental drug remdesivir coronavirus patent trials potential clinical treat respond tuesday license outbreak patients filed fight immediately company working virus developed epidemic researchers week
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more